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Introduction: The treatment of patients with CF has continued to evolve. We hypothesised that sputum microbiology may have changed as a result
of this.
Method: Retrospective analysis of sputum microbiology from adult CF patients (1985 to 2005) using the Royal Brompton Hospital CF database.
Results: Colonisation with Pseudomonas aeruginosa or Staphylococcus aureus between 1985 and 2005 remained stable (77 to 82%, p=0.159; 54
to 47%, p=0.108; respectively). Haemophilus influenzae (48 to 6%; pb0.001), Aspergillus species (18 to 9%; p=0.002) and Burkholderia
cepacia complex (9 to 4%; p=0.041) prevalence decreased. Stenotrophomonas maltophilia and MRSA increased (1 to 4%, p=0.02; 1 to 6%,
p=0.002, respectively).
Conclusion: P. aeruginosa colonisation has remained stable; there has been a decline in B. cepacia complex, H. influenzae and Aspergillus sp.,
and only a small increase in S. maltophilia and MRSA. Intensive antibiotic strategies have been employed, which, so far, have not resulted in
clinically significant emergence of new pathogens.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Sputum; Pathogens; Colonisation1. Introduction
Cystic Fibrosis (CF) is characterized by chronic endobron-
chial infection and progressive obstructive lung disease [1].
Much of the treatment for CF is aimed at preventing pulmonary
exacerbations and maintaining lung function since repeated
infections and poor lung function are associated with reduced
survival [2]. A number of organisms are responsible for
pulmonary exacerbations and some, namely P. aeruginosa and
B. cepacia complex, have been shown to lead to a more rapid
decline in lung function and an increase in mortality [3,4].
It is widely accepted that intensive antibiotic therapy of
bacterial airway infection is one of the main reasons for the⁎ Corresponding author. Royal Brompton Hospital, Sydney Street, London,
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doi:10.1016/j.jcf.2009.08.003dramatic increase in life expectancy seen over the last few
decades [5]. The “antibiotic era” [6] however brought with it
concerns of both increased antibiotic resistance and of new
pathogen emergence [7].
Mearns et al. looked at the bacterial flora of the respiratory
tract of children with cystic fibrosis between 1950 and 1971 to
see if there were any changes in the prevalence of pathogens
over time: a study which clearly showed a fall in isolation rates
of S. aureus and a rise in P. aeruginosa [8]. However, to date,
no study has been conducted to see how the trends of pathogens
have changed in adults over a similar time period. The present
study therefore focuses on the prevalence of pathogens
colonising the respiratory tract of adult CF patients at our
specialist centre between 1985 and 2005, to assess the trends
and how the prevalence has changed over this period. During
this time, the care and treatment of patients with CF has
continued to evolve. Therefore, we hypothesised that sputum
microbiology would have changed as a result of this, with and by Elsevier B.V. All rights reserved.
Fig. 1. Bacterial flora of the respiratory tract of all adult patients with cystic fibrosis, 1985–2005.
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problem in the CF airway.
2. Methods
A retrospective analysis using data from the Royal Brompton
Hospital (RBH) CF database was performed. Since 1965 details
of all patients referred to the RBH and confirmed to have CF
have been entered onto the database. The diagnosis is based on
clinical features and a positive sweat sodium (N70 mmol/L) or
chloride (N60 mmol/L) or, in cases with a borderline sweat test
result, the presence of a known disease-causing mutation on
each CFTR gene or of an abnormal nasal potential difference
measurement. Data is updated each year at annual review.Fig. 2. Bacterial flora in patients aThe analysis included all patients registered on the database
(N15 years of age) who had sputum microbiological data
available at 5-year periods from 1985 to 2005. Data from 1985,
1990, 1995, 2000 and 2005 were analysed. If a patient was
registered but no sputum was collected for that year they were
not included in the final analysis. If sputum was produced but
no pathogens isolated, this was recorded as no significant
growth. Pathogens were recorded as present if sputum cultures
were positive, intermittently or persistently, for the preceding
year leading up to annual review and the prevalence was
calculated as a percentage of the overall available patient data
for each 5-year period. FEV1 (% of predicted normal values for
sex, height and age) and BMI (kg/m2) between 1985 and 2005
were also recorded.ged 16–25 years, 1985–2005.
Fig. 3. Bacterial flora in patients aged 26–39 years, 1985–2005.
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patients in 1985, 173 patients in 1990, 339 patients in 1995, 323
patients in 2000 and 391 patients in 2005. Analyses by sex and
age groups (16–25 years, 26–39 years and 40+ years) were also
performed.
Paired t-tests or Pearson chi squared tests were performed to
see if any changes in the trends of pathogens, FEV1 or BMI
from 1985 to 2005, were significant. In both tests, pb0.05 was
regarded as significant. All patients had consented for their
anonymised data to be included in the database for research
purposes.
3. Results
The results for sputum pathogens are shown in Figs. 1–4;
Fig. 1 demonstrates the overall prevalence for all patients and
Figs. 2–4 subdivide this by age. Between 1985 and 2005, thereFig. 4. Bacterial flora in patientswas no significant change in the proportion of patients
colonised with P. aeruginosa (77% of patients in 1985
compared with 82% in 2005; p=0.159) or S. aureus (54% in
1985 to 47% in 2005; p=0.108). In 2005, the proportion of
patients with P. aeruginosa and S. aureus was not different
across the age groups. However, between 1985 and 2005, levels
of S. aureus significantly decreased in the 26–39 year age
group (58% to 40%; p=0.002).
The proportion of patients colonised with S. maltophilia
significantly increased from 1% to 4% (1985 to 2005; p=0.02).
In 2005 the proportion of patients with S. maltophilia was
significantly higher (p=0.029) amongst the 16–25s (7%)
compared to the over 25s (3% amongst the 26–39s, 1%
amongst the 40+ age group).
The proportion of patients with MRSA also significantly
increased. One percent of patients had MRSA in 1985,
increasing to 6% in 2005 (p=0.002). The proportion of patientsaged 40+ years, 1985–2005.
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many patients (8%) had MRSA in the 40+ age group compared
to the 16–25 year age group (4%).
The proportion of patients colonised with H. influenzae and
Aspergillus species significantly decreased from 48% to 6%
(1985 to 2005; pb0.001) and 18% to 9% (1985 to 2005;
p=0.002), respectively. In 2005, colonisation withH. influenzae
was similar across the different age groups. Aspergillus sp. did
not change significantly in the 26–39 and the 40+ age groups
(14 to 4% (p=0.492) and 25 to 4% (p=0.599), between 1985
and 2005, respectively), but increased significantly (pb0.001) in
the 16–25 year age group (13 to 19% between 1985 and 2005).
The proportion of patients colonised with B. cepacia
complex significantly increased from 0 to 4% between 1985
and 2005 (p=0.003) but significantly decreased from 9 to 4%
between 1990 and 2005 (p=0.041). In 2005 there was no
difference across the age groups.
Levels of S. pneumoniae, Klebsiella and M. tuberculosis
(3, 3 and 1% respectively in 1985) all decreased, with no
patients colonised with any of these pathogens in 2005. The
prevalence of atypical mycobacteria and Achromobacter
xylosoxidans increased from 1 to 3% and 0 to 2% between
1985 and 2005, respectively. Atypical mycobacteria were more
prevalent amongst the 16–25s (4%) and the 26–39s (3%)
compared to the 40+ age group (1%). The proportion of patients
with no significant growth increased from 0 to 2% (1985 to
2005; p=0.044). In 2005, the highest prevalence (3%) was in
the 16–25 age group, followed by the 26–39 age group (2%)
and then the 40+ age group (1%). There was no significant
difference in the proportion of male and female patients
colonised with a particular pathogen in 2005 (data not shown).
Mean FEV1 and BMI both increased significantly (p=0.008
and pb0.001 respectively) between 1985 and 2005 (Fig. 5).Fig. 5. Mean FEV1 and4. Discussion
The changing trends of sputum microbiology in 1421 CF
patients from our specialist centre, spanning a 20 year period
from 1985, are reported. During this time period, major
advances in the care and treatment of CF patients have occurred
and therefore we wished to assess the potential impact of these
on sputum pathogens.
The proportion of patients colonised with P. aeruginosa, as
shown from the 2005 figures, remains very high but there is
relative stability over the 20 year time period. Intensive
antibiotic therapy, including inhaled antibiotics such as
colomycin (used for attempted eradication and chronic
suppression treatment [3]), have been increasingly used during
this period. When this was first introduced in the early 1980s
[9] it was reserved for the sickest patients, but by 1986 over
65% of patients with P. aeruginosa colonisation were receiving
it in our centre. We now aim to have all patients with chronic
P. aeruginosa colonisation on an inhaled antibiotic but due to
factors, such as intolerance and non-adherence, this figure is
approximately 85%. Throughout the 20 year period, if intrave-
nous antibiotics were required for a pseudomonal infective
exacerbation, two antibiotics with activity against P. aeruginosa
were used— namely a cephalosporin or penicillin, together with
an aminoglycoside. The unit did not adopt the policy of regular
three monthly antibiotics as recommended by some centres [10]
but monitored patients carefully and treated when symptoms
and lung function and/or oxygen saturations indicated treatment
was required. While the results show there has been no increase
overall in P. aeruginosa, there is some suggestion from Fig. 1
that P. aeruginosa could be on the increase and therefore this
trend will continue to be closely monitored. The levels of S.
aureus have also remained relatively stable. The policy in ourBMI, 1985–2005.
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pathogen but in spite of this there was relatively little change in
its prevalence.
The highly significant decline in H. influenzaemay be due to
the widespread use of antibiotics such as amoxicillin and other
antibiotics primarily used to treat P. aeruginosa but with
concurrent activity against H. influenzae, such as imipenem
(used from the mid-1980s) and meropenem (used widely from
the early 1990s). More recently, azithromycin as an anti-
inflammatory agent has been used increasingly; it is also active
against organisms such as H. influenzae and S. aureus and may
lead to a decrease in their prevalence in the future, although
conversely it may encourage growth of resistant organisms
and therefore close monitoring of these potential outcomes is
required [11,12].
Although the prevalence of P. aeruginosa and S. aureus has
remained relatively stable since the introduction of prophylactic/
chronic antibiotic treatment, the question still remains as to
whether it has encouraged the growth of other pathogens such as
MRSA, S. maltophilia and A. xyloxidans. Burns et al. evaluated
long-term tobramycin solution for inhalation (TSI) and showed
no association with increased isolation of organisms such as
S. maltophilia, A. xylosoxidans or B. cepacia complex [13].
From the present study, the prevalence of B. cepacia
complex has reassuringly decreased significantly after its initial
increase in the late 1980s. Awareness of the importance of this
pathogen in CF occurred only after Isles et al. published their
findings in 1984; subsequently, microbiological recognition
improved and, therefore, so did identification rates [14,15]. The
decline in prevalence of this organism may be a reflection of
increasing use of single rooms for inpatients, followed later by
clinic segregation policies [16,17], which were introduced in
our unit in October 2000.
Despite intensive use of inhaled antibiotics in our centrewe did
not see an overall increase in Aspergillus sp. levels contrary to
earlier predictions. Interestingly, Burns et al. did demonstrate
this — we therefore hypothesise that this could be a result of
differing antibiotic use. Burns' study used tobramycin over a short
period whereas patients at the Royal Brompton Hospital have
been treated with colomycin since the 1980s. An inconsistency
and argument against this, however, is that the prevalence
of Aspergillus sp. and S. maltophilia increased in the younger
age groups. A possible reason for this was more frequent use
of inhaled antibiotics at a younger age. This has important
implications for the future, especially with the introduction of
newborn screening, as treatment at an early age may have risks as
well as benefits. We identified a low proportion of 40+ year olds
with atypical mycobacteria, contrary to recent study of this age
group in North America [18]. The reason for this is uncertain. It
may be due to the composition of the group (i.e. mild phenotypes)
or differing geographical locations.
The increase in the number of patients with no significant
growth of any organism in their sputum was low but appears
to be steadily increasing. This could reflect an increasing
proportion of patients with milder disease — which may be a
result of better treatment and/or an increase in the diagnosis of
milder phenotypes. It could also be due to changing clinicalpractice, as the use of intensive treatment regimens to attempt
eradication of organisms when they are first isolated, is common
practice now in most centres.
Over the 20 year period microbiological identification
techniques have improved, including new and refined media
to help in the isolation of the ‘new’ respiratory pathogens, e.g.
B. cepacia complex, S. maltophilia and A. xylosoxidans.
Improved biochemical systems, closed automated systems and
molecular typing has improved identification and separation of
different species. From the observations of the present study,
despite these new techniques, the prevalence of pathogens has
not significantly increased and only small numbers of the
‘newer’ pathogens are currently being recognised.
A comparison between 2005 figures from our unit and those
taken from the US annual data registry for 2005 [19] showed
our unit had a higher proportion of patients with S. aureus (47%
vs 35%), lower levels of MRSA (6% vs 16%) and S. maltophilia
(4% vs 11%), and remarkably similar levels of P. aeruginosa
(82% vs 78%), H. influenzae (both 6%) and B. cepacia complex
(4% vs 5%). Direct comparison is difficult as microbiological
surveillance and treatments may vary, but our low levels of
MRSA and S. maltophilia are an important observation —
further investigation of the cause is required, including
differences in antibiotic prescribing and cross-infection control
strategies.
One of the goals of treatment in CF is to preserve lung
function since rapid decline is a known risk factor for mortality
[20]. The significant increase in mean FEV1 in this cross-
sectional study shows this goal is being achieved. Pulmonary
exacerbations cause significant morbidity and ultimately lead to
a decline in lung function [21] and therefore early identification
and treatment is crucial [3]. Since chronic P. aeruginosa
infection is associated with a more rapid decline in lung
function, aggressive use of inhaled anti-pseudomonal antibio-
tics such as colomycin and tobramycin have become wide-
spread [22,23]. Other treatments, such as daily physiotherapy
(including exercise), DNase and nebulised hypertonic saline
play an important role in airway clearance and help to prevent
exacerbations [3]. These treatment strategies in younger
patients, along with prophylactic anti-staphylococcal antibiotics
may have contributed to the increase in mean FEV1 but for other
treatments, such as azithromycin, it is too early to assess.
BMI is considered a good marker of nutritional status,
which, in turn, predicts survival [24]. The combination of poor
weight and poor pulmonary function combine to predict a worse
prognosis [25], therefore the significant increase in mean FEV1
and BMI seen between 1985 and 2005 is hugely encouraging.
The BMI increased from 1990 which may have been due to the
introduction of the enteric coated microspheres.
The success of the ‘antibiotic era’ has so far been unhindered
by previous fears of clinically significant emergence of new
pathogens, but we will need to continue to monitor closely the
trends of pathogens such as MRSA, S. maltophilia and A.
xylosoxidans. Antibiotic use has been one of many therapies to
have contributed to improved lung function and ultimately
survival of CF patients. Reducing the endobronchial microbial
burden, especially of P. aeruginosa and B. cepacia complex,
391F.A. Millar et al. / Journal of Cystic Fibrosis 8 (2009) 386–391will continue to be a primary goal of CF care, combined with
minimizing cross-infection between patients, careful microbi-
ological surveillance and early and intensive treatment. It is
uncertain how earlier intensive treatment of children with CF
will affect the adult CF population in future years.
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